Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Subscribe To Our Newsletter & Stay Updated
